The case for a medication first approach to the treatment of opioid use disorder

References

• Centers for Disease Control and Prevention. HAN00413: rising numbers of feaths involving fentanyl and fentanyl analogs, including carfentanil, and increased usage and mixing with non-opioids [Internet]. Health Alert Network. 2018 [cited 2019 Jan 2]. Available from: https://emergency.cdc.gov/han/han00413.asp
   Google Scholar
• Connery HS. Medication-assisted treatment of opioid use disorder. Harv Rev Psychiatry. 2015;23(2):63–75. doi:10.1097/HRP.0000000000000075. Cited in PubMed; PMID:25747920.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017 Apr 26;357:j1550. doi: 10.1136/bmj.j1550. Cited in PubMed; PMID:28446428
   PubMed Web of Science ®Google Scholar
• Ma J, Bao Y-P, Wang R-J, Su M-F, Liu M-X, Li J-Q, Degenhardt L, Farrell M, Blow FC, Ilgen M, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2018 Jun 22; 1. doi: 10.1038/s41380-018-0094-5.
   Web of Science ®Google Scholar
• U.S. Food & Drug Administration Center for Drug Evaluation and Research. Information by drug class - information about medication-assisted treatment (mat) [Internet]. Center for Drug Evaluation and Research; 2018 [cited 2019 Jan 4]. Available from: https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm600092.htm
   Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014 Feb 6;2:CD002207. doi: 10.1002/14651858.CD002207.pub4. Cited in PubMed; PMID:24500948
   PubMed Web of Science ®Google Scholar
• Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016 Jan 2;35(1):22–35. doi:10.1080/10550887.2016.1100960.
   PubMed Web of Science ®Google Scholar
• Nosyk B, Anglin MD, Brissette S, Kerr T, Marsh DC, Schackman BR, Wood E, Montaner JSG. A call for evidence-based medical treatment of opioid dependence in the united states and canada. Health Aff. 2013 Aug 2;32(8):1462–69. doi:10.1377/hlthaff.2012.0846.
   Web of Science ®Google Scholar
• Fiscella K, Wakeman SE, Beletsky L. Implementing opioid agonist treatment in correctional facilities. JAMA Intern Med. 2018 Sep 1;178(9):1153. doi:10.1001/jamainternmed.2018.3504.
   PubMed Web of Science ®Google Scholar
• Aletraris L, Edmond MB, Paino M, Fields D, Roman PM. Counselor training and attitudes toward pharmacotherapies for opioid use disorder. Subst Abus. 2016 Jan 2;37(1):47–53. doi: 10.1080/08897077.2015.1062457. Cited in PubMed; PMID:26168816
   PubMed Web of Science ®Google Scholar
• Sigmon SC. Access to treatment for opioid dependence in rural america. JAMA Psychiatry. 2014 Apr 1;71(4):359. doi:10.1001/jamapsychiatry.2013.4450.
   PubMed Web of Science ®Google Scholar
• Lee JD, E V N, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (x: bot):a multicentre, open-label, randomised controlled trial. Lancet. 2018 Jan 27; 391(10118):309–18. doi:10.1016/S0140-6736(17)32812-X.
   PubMed Web of Science ®Google Scholar
• Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a united states commercially insured population. J Subst Abuse Treat. 2018 Feb;85:90–96. 10.1016/j.jsat.2017.07.001.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018 Jun;19. doi: 10.7326/M17-3107.
   Web of Science ®Google Scholar
• Bhatraju EP, Grossman E, Tofighi B, McNeely J, DiRocco D, Flannery M, Garment A, Goldfeld K, Gourevitch MN, Lee JD. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Addict Sci Clin Pract. 2017;12(1):7. doi:10.1186/s13722-017-0072-2. Cited in PubMed; PMID:28245872.
   PubMed Web of Science ®Google Scholar
• Madden LM, Farnum SO, Eggert KF, Quanbeck AR, Freeman RM, Ball SA, Schottenfeld RS, Shi JM, Savage ME, Barry DT. An investigation of an open-access model for scaling up methadone maintenance treatment. Addiction. 2018 Aug;113(8):1450–58. doi: 10.1111/add.14198. Cited in PubMed; PMID:29453891.
   PubMed Web of Science ®Google Scholar
• Arfken CL, Johanson C-E, Di Menza S, Cr S. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat. 2010 Sep;39(2):96–104. doi: 10.1016/j.jsat.2010.05.004. Cited in PubMed; PMID:20598829.
   PubMed Web of Science ®Google Scholar
• Sm M, Ke M, Ja L, Yang X, Pj J, Jd L, Nunes EV, Novo P, Rotrosen J, Br S. Cost-effectiveness of buprenorphine–naloxone versus extended-release naltrexone to prevent opioid relapse. Ann Intern Med. 2018 Dec 18. doi:10.7326/M18-0227. Cited in PubMed; PMID:30557443.
   Web of Science ®Google Scholar
• Substance Abuse and Mental, Health Services Administration, Substance Abuse and Mental Health Services Administration. National survey of substance abuse treatment services (n-ssats): 2017 data on substance abuse treatment facilities [Internet]. Rockville, MD; 2018 [cited 2018 Dec 21].
   Google Scholar
• Andrilla CHA, Coulthard C, Larson EH. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Ann Fam Med. 2017 Jul 1;15(4):359–62. doi: 10.1370/afm.2099. Cited in PubMed; PMID:28694273
   PubMed Web of Science ®Google Scholar
• Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018 Jun 1;54(6):S230–42. doi:10.1016/J.AMEPRE.2017.12.022.
   PubMed Web of Science ®Google Scholar
• Hutchinson E, Catlin M, Andrilla CHA, Baldwin L-M, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014 Mar 1;12(2):128–33. doi: 10.1370/afm.1595. Cited in PubMed; PMID:24615308.
   PubMed Web of Science ®Google Scholar
• van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Healthcare professionals’ regard towards working with patients with substance use disorders: comparison of primary care, general psychiatry and specialist addiction services. Drug Alcohol Depend. 2014 Jan 1;134:92–98. doi:10.1016/J.DRUGALCDEP.2013.09.012.
   PubMed Web of Science ®Google Scholar
• Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015 Aug;105(8):e55–63. doi: 10.2105/AJPH.2015.302664. Cited in PubMed; PMID:26066931.
   PubMed Web of Science ®Google Scholar
• Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011 Jun 1;36(6):584–89. doi:10.1016/J.ADDBEH.2011.01.032.
   PubMed Web of Science ®Google Scholar
• Molfenter T, Sherbeck C, Zehner M, Quanbeck A, McCarty D, Kim J-S SS. Implementing buprenorphine in addiction treatment: payer and provider perspectives in ohio. Subst Abuse Treat Prev Policy. 2015 Dec 28;10(1):13. doi:10.1186/s13011-015-0009-2.
   PubMed Web of Science ®Google Scholar
• Pearson CF, Brantley K Midwest and mid-atlantic states face provider shortage to address opioid epidemic [Internet]. 2018 [cited 2019 Jan 4]. Available from: https://avalere.com/press-releases/midwest-and-mid-atlantic-states-face-provider-shortage-to-address-opioid-epidemic?utm_source=newsletter&utm_medium=email&utm_campaign&stream=top-stories
   Google Scholar
• LA S, Rieckmann T, Abraham A, Molfenter T, Capoccia V, Roman P, Dh G, McCarty D. Advancing recovery: implementing evidence-based treatment for substance use disorders at the systems level. J Stud Alcohol Drugs. May2012;73(3):413–22. doi: 10.15288/jsad.2012.73.413 Cited in PubMed; PMID:22456246.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. SAMHSA grant awards for mat-pdoa (ti-15-007) [Internet]. [cited 2019 Jan 4]. Available from: https://www.samhsa.gov/grants/awards/mat-pdoa
   Google Scholar
• Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O’Connor PG. Primary care–based buprenorphine taper vs maintenance therapy for prescription opioid dependence. JAMA Intern Med. 2014;174(12):1947. doi:10.1001/jamainternmed.2014.5302. Cited in PubMed; PMID:25330017.
   PubMed Web of Science ®Google Scholar
• Bentzley BS, Barth KS, Back SE, Book SW. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat. 2015 May;52:48–57. doi: 10.1016/j.jsat.2014.12.011. Cited in PubMed; PMID:25601365
   PubMed Web of Science ®Google Scholar
• Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med. Jan 2001;68(1):62–74. Cited in PubMed; PMID:11135508.
   PubMed Web of Science ®Google Scholar
• Missouri Secretary of State. Rules of department of mental health division 30-certification standards chapter 3-substance use disorder treatment programs [Internet]. Code of State Regulations 2018 p. 12–16.
   Google Scholar
• Tsai J, Rosenheck RA. Considering alternatives to the housing first model. Eur J Homelessness. 2012;6(2):201–208.
   Google Scholar
• Tsemberis S, Gulcur L, Nakae M. Housing first, consumer choice, and harm reduction for homeless individuals with a dual diagnosis. Am J Public Health. 2004 Apr;94(4):651–56. doi: 10.2105/AJPH.94.4.651. Cited in PubMed; PMID:15054020.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Mannelli P, Sullivan MA, Vosburg SK, Compton P, Woody GE, Kosten TR. Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies. Am J Addict. 2018 Apr 1;27(3):177–87. doi:10.1111/ajad.12711.
   PubMed Web of Science ®Google Scholar
• Aubry T, Nelson G, Tsemberis S. Housing first for people with severe mental illness who are homeless: a review of the research and findings from the at home—chez soi demonstration project. Can J Psychiatry. 2015 Nov 1;60(11):467–74. doi:10.1177/070674371506001102.
   PubMed Web of Science ®Google Scholar
• Stringer M. Letter to the editor: ‘medication first’ not the same as ‘medication. Alcohol Drug Abus Wkly.. 2018 Aug 27;30(33):6–6. doi:10.1002/adaw.32087.
   Google Scholar
• Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):93–103. doi:10.1097/ADM.0000000000000193. Cited in PubMed; PMID:26808307.
   PubMed Web of Science ®Google Scholar
• Bagra I, Krishnan V, Rao R, Agrawal A. Does cannabis use influence opioid outcomes and quality of life among buprenorphine maintained patients? a cross-sectional, comparative study. J Addict Med. 2018;12(4):315–20. doi:10.1097/ADM.0000000000000406. Cited in PubMed; PMID:29543612.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA drug safety communication: fda urges caution about withholding opioid addiction medications from patients taking benzodiazepines or cns depressants: careful medication management can reduce risks [Internet]. Center for Drug Evaluation and Research; 2017 [cited 2018 Dec 21].
   Google Scholar
• Marlatt GA, Blume AW, Parks GA. Integrating harm reduction therapy and traditional substance abuse treatment. J Psychoactive Drugs. 2001 Mar 6;33(1):13–21. doi: 10.1080/02791072.2001.10400463. Cited in PubMed; PMID:11332996
   PubMed Web of Science ®Google Scholar
• Kertesz SG, Johnson G. Housing first: lessons from the united states and challenges for australia. Aust Econ Rev. 2017 Jun 1;50(2):220–28. doi:10.1111/1467-8462.12217.
   Web of Science ®Google Scholar
• Kertesz SG, Baggett TP, O’Connell JJ, Buck DS, Kushel MB. Permanent supportive housing for homeless people — reframing the debate. N Engl J Med. 2016 Dec 30;375(22):2115–17. doi:10.1056/NEJMp1608326.
   PubMed Web of Science ®Google Scholar
• United States District Court District of Massachusetts. Civil action no. 18-11972-djc [Internet]. 2018 [cited 2019 Jan 3].
   Google Scholar
• Ryan RM, Lynch MF, Vansteenkiste M, Deci EL. Motivation and autonomy in counseling, psychotherapy, and behavior change: a look at theory and practice 1ψ7. Couns Psychol. 2011. doi:10.1177/0011000009359313.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence [Internet]. 2009 [cited 2019 Jan 30].
   Google Scholar
• Meader N. A comparison of methadone, buprenorphine and alpha2 adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis. Drug Alcohol Depend. 2010 Apr 1;108(1–2):110–14. doi:10.1016/J.DRUGALCDEP.2009.12.008.
   PubMed Web of Science ®Google Scholar
• Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012 Jul;31(3):207–25. doi: 10.1080/10550887.2012.694598. Cited in PubMed; PMID:22873183.
   PubMed Web of Science ®Google Scholar
• Pollack HA, D’Aunno T. Dosage patterns in methadone treatment: results from a national survey, 1988-2005. Health Serv Res. 2008 Dec;43(6):2143–63. doi: 10.1111/j.1475-6773.2008.00870.x. Cited in PubMed; PMID:18522665.
   PubMed Web of Science ®Google Scholar
• Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011 Oct 5;(10). doi: 10.1002/14651858.CD004147.pub4.
   Web of Science ®Google Scholar
• Bassuk EL, Hanson J, Greene RN, Richard M, Laudet A. Peer-delivered recovery support services for addictions in the united states: a systematic review. J Subst Abuse Treat. 2016 Apr 1;63:1–9. doi:10.1016/J.JSAT.2016.01.003.
   PubMed Web of Science ®Google Scholar
• Reif S, Braude L, Lyman DR, Dougherty RH, Daniels AS, Ghose SS, Salim O, Delphin-Rittmon ME. Peer recovery support for individuals with substance use disorders: assessing the evidence. Psychiatr Serv. 2014 May;19:1–9. doi: 10.1176/appi.ps.201400047. Cited in PubMed; PMID:24838535
   Web of Science ®Google Scholar
• Miller WR, Wilbourne PL. Mesa grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction. Mar 2002;97(3):265–77. Cited in PubMed; PMID:11964100.
   PubMed Web of Science ®Google Scholar
• Amato L, Davoli M, Vecchi S, Ali R, Farrell M, Faggiano F, Foxcroft D, Ling W, Minozzi S, Chengzheng Z. Cochrane systematic reviews in the field of addiction: what’s there and what should be. Drug Alcohol Depend. 2011 Jan 15;113(2–3):96–103. doi: 10.1016/j.drugalcdep.2010.08.003. Cited in PubMed; PMID:20832954
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Treatment. Physical detoxification services for withdrawal from specific substances. Treatment Improvement Protocol (TIP) Series, No 45: detoxification and Substance Abuse Treatment. Rockville, MD:Substance Abuse and Mental Health Services Administration (US);2006. p. 47–119. cited 2019 Jan 7
   Google Scholar
• Mojtabai R, Crum RM. Perceived unmet need for alcohol and drug use treatments and future use of services: results from a longitudinal study. Drug Alcohol Depend. 2013 Jan 1;127(1–3):59–64. doi: 10.1016/j.drugalcdep.2012.06.012. Cited in PubMed; PMID:22770461
   PubMed Web of Science ®Google Scholar
• Bose J, Hedden SL, Lipari RN, Park-Lee E, Tice P Key substance use and mental health indicators in the united states: results from the 2017 national survey on drug use and health [Internet]. 2018 [cited 2018 Sep 14].
   Google Scholar
• Corrigan PW, Nieweglowski K. Stigma and the public health agenda for the opioid crisis in america. Int J Drug Policy. 2018;59:44–49. doi: 10.1016/j.drugpo.2018.06.015. Cited in PubMed; PMID:29986271.
   PubMed Web of Science ®Google Scholar